S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
Log in

TSE:PLI - ProMetic Life Sciences Stock Price, Forecast & News

Today's Range N/A
50-Day Range
C$13.54
MA: C$13.54
C$13.54
52-Week Range N/A
Volume302 shs
Average Volume8,002 shs
Market CapitalizationC$315.66 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Prometic Life Sciences Inc operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. Read More…

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-450-7810115

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$39.91 million
Book ValueC$6.07 per share

Profitability

Miscellaneous

Employees487
Market CapC$315.66 million
Next Earnings DateN/A
OptionableNot Optionable

Receive PLI News and Ratings via Email

Sign-up to receive the latest news and ratings for PLI and its competitors with MarketBeat's FREE daily newsletter.


ProMetic Life Sciences (TSE:PLI) Frequently Asked Questions

What is ProMetic Life Sciences' stock symbol?

ProMetic Life Sciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "PLI."

What price target have analysts set for PLI?

3 Wall Street analysts have issued 1 year price targets for ProMetic Life Sciences' shares. Their forecasts range from C$0.30 to C$0.70. On average, they anticipate ProMetic Life Sciences' stock price to reach C$0.50 in the next year. View Analyst Price Targets for ProMetic Life Sciences.

What is the consensus analysts' recommendation for ProMetic Life Sciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProMetic Life Sciences in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ProMetic Life Sciences.

Has ProMetic Life Sciences been receiving favorable news coverage?

News headlines about PLI stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ProMetic Life Sciences earned a daily sentiment score of -2.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for ProMetic Life Sciences.

Who are some of ProMetic Life Sciences' key competitors?

What other stocks do shareholders of ProMetic Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProMetic Life Sciences investors own include Nemaska Lithium (NMX), ProMetic Life Sciences (PFSCF), Bombardier, Inc. Class B (BBD.B), Crescent Point Energy (CPG), Sierra Wireless (SWIR), Baytex Energy (BTE), Dollarama (DOL), Parkland Fuel (PKI), Aurora Cannabis (ACB) and Resverlogix (RVX).

Who are ProMetic Life Sciences' key executives?

ProMetic Life Sciences' management team includes the folowing people:
  • Mr. Kenneth H. Galbraith, CEO & Director (Age 56)
  • Mr. Bruce Pritchard, International COO & Interim CFO
  • Mr. Patrick Sartore, Chief Legal Officer & Corp. Sec.
  • Mr. Bruce Wendel, Chief Bus. Devel. Officer (Age 65)
  • Dr. John Moran, Chief Medical Officer (Age 73)

How do I buy shares of ProMetic Life Sciences?

Shares of PLI and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

How big of a company is ProMetic Life Sciences?

ProMetic Life Sciences has a market capitalization of C$0.00 and generates C$39.91 million in revenue each year. ProMetic Life Sciences employs 487 workers across the globe.View Additional Information About ProMetic Life Sciences.

What is ProMetic Life Sciences' official website?

The official website for ProMetic Life Sciences is http://prometic.com/.

How can I contact ProMetic Life Sciences?

ProMetic Life Sciences' mailing address is 440 Armand-Frappier Blvd Suite 300, LAVAL, QC H7V 4B4, Canada. The company can be reached via phone at +1-450-7810115.


MarketBeat Community Rating for ProMetic Life Sciences (TSE PLI)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  431 (Vote Outperform)
Underperform Votes:  400 (Vote Underperform)
Total Votes:  831
MarketBeat's community ratings are surveys of what our community members think about ProMetic Life Sciences and other stocks. Vote "Outperform" if you believe PLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Featured Article: Trade War

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel